The Aim of this research work was to develop sustained release bilayer dosage form by using Metformin Hydrochloride and Glimepiride that can help to provide synergistic effect for the therapeutic management of Diabetes. Bilayer dosages form was developed and determines the sustained release effect of both Metformin Hydrochloride and Glimepiride by using various polymers as MCC PH 102, Starch paste, Ethyl cellulose, Eudragit RLPO etc. at different concentration. As tested by FTIR the excipients cast-off in this research did not modify physicochemical properties of the drug. Formulated batches were assessed for thickness, weight variation, hardness and drug content uniformity. USP apparatus II was used for in vitro drug dissolution study whic...
Diabetes is one of the major causes of death and disability in the world. Diabetes results from decr...
Objective: The main objective of the present investigation is to develop a sustained-release (SR) fo...
In 1985, there were approximately 30 million people with diabetes worldwide; by 1995, this number ha...
The aim of the present study was to design and evaluate bilayered tablets of metformin hydrochloride...
The present study was carried out for developing the formulation of Bilayer tablets of Glimepiride, ...
The aim of present study is to formulate and evaluate the bilayered tablets containing immediate rel...
Metformin is an oral antidiabetic biguanide drug for the treatment of type 2 diabetes, in particular...
<p>Bi-layer tablet is a new era for successful development of controlled release formulation along w...
Diabetes Mellitus (T2DM) is one of the complex metabolic disorders with multiple effects. Hypertensi...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
The Glimepiride floating tablet is prepared with various polymer of guar gum; xanthan gum and carbop...
Abstract The aim of the current study is to design a sustained release matrix tablet of metformin HC...
This study is to formulate Metformin and Glimepiride in Bi-layer tablet dosage form and evaluate di...
Metformin hydrochloride is recommended globally as first line therapy due to its favorable profile o...
Metformin HCL, the only biguanide still in use today, reduces peripheral insulin resistance and hepa...
Diabetes is one of the major causes of death and disability in the world. Diabetes results from decr...
Objective: The main objective of the present investigation is to develop a sustained-release (SR) fo...
In 1985, there were approximately 30 million people with diabetes worldwide; by 1995, this number ha...
The aim of the present study was to design and evaluate bilayered tablets of metformin hydrochloride...
The present study was carried out for developing the formulation of Bilayer tablets of Glimepiride, ...
The aim of present study is to formulate and evaluate the bilayered tablets containing immediate rel...
Metformin is an oral antidiabetic biguanide drug for the treatment of type 2 diabetes, in particular...
<p>Bi-layer tablet is a new era for successful development of controlled release formulation along w...
Diabetes Mellitus (T2DM) is one of the complex metabolic disorders with multiple effects. Hypertensi...
Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochlori...
The Glimepiride floating tablet is prepared with various polymer of guar gum; xanthan gum and carbop...
Abstract The aim of the current study is to design a sustained release matrix tablet of metformin HC...
This study is to formulate Metformin and Glimepiride in Bi-layer tablet dosage form and evaluate di...
Metformin hydrochloride is recommended globally as first line therapy due to its favorable profile o...
Metformin HCL, the only biguanide still in use today, reduces peripheral insulin resistance and hepa...
Diabetes is one of the major causes of death and disability in the world. Diabetes results from decr...
Objective: The main objective of the present investigation is to develop a sustained-release (SR) fo...
In 1985, there were approximately 30 million people with diabetes worldwide; by 1995, this number ha...